ALLO Logo

Allogene Therapeutics, Inc. (ALLO) 

NASDAQ
Market Cap
$674.39M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
50 of 776
Rank in Industry
39 of 433

Largest Insider Buys in Sector

ALLO Stock Price History Chart

ALLO Stock Performance

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin …

Insider Activity of Allogene Therapeutics, Inc.

Over the last 12 months, insiders at Allogene Therapeutics, Inc. have bought $5M and sold $118,986 worth of Allogene Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Allogene Therapeutics, Inc. have bought $6.97M and sold $28.81M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Belldegrun Arie (director) — $5M. Parker Geoffrey M. (CHIEF FINANCIAL OFFICER) — $2,049.

The last purchase of 1,724,137 shares for transaction amount of $5M was made by Belldegrun Arie (director) on 2024‑05‑16.

List of Insider Buy and Sell Transactions, Allogene Therapeutics, Inc.

2024-06-18Saledirector
18,641
0.008%
$2.28$42,488+19.28%
2024-05-30Saledirector
11,200
0.0051%
$2.34$26,181+7.11%
2024-05-16Purchasedirector
1.72M
0.9747%
$2.90$5M-12.33%
2024-01-30PurchaseCHIEF FINANCIAL OFFICER
190
0.0001%
$3.60$683-20.83%
2023-12-18Saledirector
18,640
0.0103%
$2.70$50,317+1.72%
2023-08-07Saledirector
10,000
0.0069%
$4.29$42,855-25.59%
2023-02-13SaleGeneral Counsel
3,000
0.002%
$6.85$20,550-40.59%
2023-01-17SaleGeneral Counsel
3,000
0.0021%
$7.04$21,120-31.37%
2022-12-15SaleGeneral Counsel
5,602
0.0041%
$7.53$42,186-29.66%
2022-08-11Sale
15,000
0.0106%
$16.75$251,250-61.71%
2022-08-02SaleEVP of R&D and CMO
2,000
0.0013%
$11.97$23,940-47.84%
2022-07-05SaleEVP of R&D and CMO
2,000
0.0014%
$11.44$22,880-38.52%
2022-06-22Sale
10,000
0.0069%
$11.76$117,600-33.78%
2022-06-21SaleEVP of R&D and CMO
2,000
0.0014%
$11.18$22,360-30.17%
2022-05-19SaleEVP of R&D and CMO
11,500
0.0079%
$7.40$85,092+18.54%
2022-03-15SalePresident and CEO
23,648
0.0164%
$7.65$180,879+21.54%
2022-03-15SaleGeneral Counsel
8,849
0.0062%
$7.68$67,962+21.54%
2022-03-15SaleEVP of R&D and CMO
5,169
0.0036%
$7.71$39,848+21.54%
2022-03-15SaleChief Technical Officer
8,698
0.006%
$7.63$66,388+21.54%
2022-03-15SaleChief Financial Officer
11,469
0.0079%
$7.63$87,551+21.54%

Insider Historical Profitability

<0.0001%
Belldegrun Ariedirector
1724137
0.8245%
$3.2340<0.0001%
Parker Geoffrey M.CHIEF FINANCIAL OFFICER
819590
0.3919%
$3.2310
Humer Franz Bdirector
255253
0.1221%
$3.2311+2.3%
PFIZER INC10 percent owner
22032040
10.536%
$3.2310+2.3%
TPG Group Holdings (SBS) Advisors, Inc.10 percent owner
18716306
8.9504%
$3.23117+2.3%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$113.38M12.1725.36M+0.48%+$546,676.530.01
Tpg Gp A Llc$83.66M8.9818.72M0%+$01.62
BlackRock$43.15M4.639.65M-3.49%-$1.56M<0.01
State Street$41.05M4.419.18M+278.37%+$30.2M<0.01
The Vanguard Group$36.69M3.948.21M-9.12%-$3.68M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.